Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

800 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry.
Garrigós L, Saura C, Martinez-Vila C, Zambelli A, Bower M, Pistilli B, Lambertini M, Ottaviani D, Diamantis N, Lumsden A, Pernas S, Generali D, Seguí E, Viñas G, Felip E, Sanchez A, Rizzo G, Santoro A, Cortellini A, Perone Y, Chester J, Iglesias M, Betti M, Vincenzi B, Libertini M, Mazzoni F, Zoratto F, Berardi R, Guida A, Wuerstlein R, Loizidou A, Sharkey R, Aguilar Company J, Matas M, Saggia C, Chiudinelli L, Colomba-Blameble E, Galazi M, Mukherjee U, Van Hemelrijck M, Marin M, Strina C, Prat A, Pla H, Ciruelos EM, Bertuzzi A, Del Mastro L, Porzio G, Newsom-Davis T, Ruiz I, Delany MB, Krengli M, Fotia V, Viansone A, Chopra N, Romeo M, Salazar R, Perez I, d'Avanzo F, Franchi M, Milani M, Pommeret F, Tucci M, Pedrazzoli P, Harbeck N, Ferrante D, Pinato DJ, Gennari A. Garrigós L, et al. Among authors: milani m. Ther Adv Med Oncol. 2021 Nov 2;13:17588359211053416. doi: 10.1177/17588359211053416. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34777582 Free PMC article.
Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.
Generali D, Dovio A, Tampellini M, Tucci M, Tedoldi S, Torta M, Bonardi S, Allevi G, Aguggini S, Milani M, Harris AL, Bottini A, Dogliotti L, Angeli A, Berruti A. Generali D, et al. Among authors: milani m. Br J Cancer. 2008 Jun 3;98(11):1753-8. doi: 10.1038/sj.bjc.6604390. Epub 2008 May 27. Br J Cancer. 2008. PMID: 18506177 Free PMC article. Clinical Trial.
Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.
Mele T, Generali D, Fox S, Brizzi MP, Bersiga A, Milani M, Allevi G, Bonardi S, Aguggini S, Volante M, Dogliotti L, Bottini A, Harris A, Berruti A. Mele T, et al. Among authors: milani m. Breast Cancer Res Treat. 2010 Oct;123(3):795-804. doi: 10.1007/s10549-010-1063-0. Epub 2010 Aug 3. Breast Cancer Res Treat. 2010. PMID: 20680681 Clinical Trial.
Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity.
Ravelli A, Reuben JM, Lanza F, Anfossi S, Cappelletti MR, Zanotti L, Gobbi A, Milani M, Spada D, Pedrazzoli P, Martino M, Bottini A, Generali D; Solid Tumor Working Party of the European Blood and Marrow Transplantation Society (EBMT). Ravelli A, et al. Among authors: milani m. Expert Rev Anticancer Ther. 2015 Jun;15(6):689-702. doi: 10.1586/14737140.2015.1042864. Epub 2015 Apr 30. Expert Rev Anticancer Ther. 2015. PMID: 25927868 Review.
Neoadjuvant Treatment Approach: The Rosetta Stone for Breast Cancer?
Generali D, Ardine M, Strina C, Milani M, Cappelletti MR, Zanotti L, Forti M, Bedussi F, Martinotti M, Amoroso V, Sigala S, Simoncini E, Berruti A, Bottini A. Generali D, et al. Among authors: milani m. J Natl Cancer Inst Monogr. 2015 May;2015(51):32-5. doi: 10.1093/jncimonographs/lgv019. J Natl Cancer Inst Monogr. 2015. PMID: 26063883
Breast cancer circulating biomarkers: advantages, drawbacks, and new insights.
Ravelli A, Reuben JM, Lanza F, Anfossi S, Cappelletti MR, Zanotti L, Gobbi A, Senti C, Brambilla P, Milani M, Spada D, Pedrazzoli P, Martino M, Bottini A, Generali D; Solid Tumor Working Party of European Blood and Marrow Transplantation Society (EBMT). Ravelli A, et al. Among authors: milani m. Tumour Biol. 2015 Sep;36(9):6653-65. doi: 10.1007/s13277-015-3944-7. Epub 2015 Aug 26. Tumour Biol. 2015. PMID: 26307395 Review.
A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trial.
Roviello G, Milani M, Gobbi A, Dester M, Cappelletti MR, Allevi G, Aguggini S, Ravelli A, Gussago F, Cocconi A, Zanotti L, Senti C, Strina C, Bottini A, Generali D. Roviello G, et al. Among authors: milani m. Future Oncol. 2016 Oct;12(19):2189-93. doi: 10.2217/fon-2016-0116. Epub 2016 Jun 21. Future Oncol. 2016. PMID: 27324108 Clinical Trial.
Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer.
Milani M, Venturini S, Bonardi S, Allevi G, Strina C, Cappelletti MR, Corona SP, Aguggini S, Bottini A, Berruti A, Jubb A, Campo L, Harris AL, Gatter K, Fox SB, Generali D, Roviello G. Milani M, et al. Oncotarget. 2017 Aug 14;8(45):78870-78881. doi: 10.18632/oncotarget.20239. eCollection 2017 Oct 3. Oncotarget. 2017. PMID: 29108271 Free PMC article.
800 results